Medical Condition News

RSS

FDA extends review period for Almirall and Forest Labs' aclidinium bromide NDA

Forest Laboratories, Inc. and Almirall, S.A. announced today that the U.S. Food and Drug Administration (FDA) will require a three-month extension to complete its review of the data supporting the New Drug Application (NDA) for aclidinium bromide, a new long-acting antimuscarinic for the maintenance treatment of Chronic Obstructive Pulmonary Disease.

29 Mar 2012

One-side parathyroid surgery has poorer long-term outcomes

Dr James Norman, MD and his partners at the Norman Parathyroid Center have published a landmark study in this week's Journal of the American College of Surgeons describing how the operation they developed and advocated for more than 19 years has significantly poorer long-term outcomes. The unilateral or "one-side" parathyroid surgical procedure to remove parathyroid tumors from patients suffering from hyperparathyroidism is a dramatic change from the large neck operation that it replaced.

29 Mar 2012

Greenwood launches Syndromic Autism 62-Gene Panel

RainDance Technologies, Inc., the Digital Biology Company, today announced that Greenwood Genetic Center has commercially launched its Syndromic Autism 62-Gene Panel which was built for use on RainDance's picodroplet-based targeted sequencing platform.

29 Mar 2012

SafeStitch Medical's AMID Stapler to be presented at AHS 2012

SafeStitch Medical, Inc. will present the AMID Stapler® at the 5th International Hernia Congress in New York City, March 28-31, 2012.

29 Mar 2012

Daiichi Sankyo, NGM to discover and develop new treatments for diabetes

Daiichi Sankyo Company, Ltd. and NGM Biopharmaceuticals, Inc. announced today that they have entered into a research collaboration and license agreement to discover and develop novel therapeutics that modulate beta-cell regeneration for the treatment of diabetes.

29 Mar 2012

Obstacles standing in the way of cancer prevention

More than half of all cancer is preventable, and society has the knowledge to act on this information today, according to Washington University public health researchers at the Siteman Cancer Center in St. Louis.

29 Mar 2012

Study calls for re-examination of criteria used to prioritize liver transplant candidates

Patients with end-stage liver disease complicated by the most common type of liver cancer - hepatocellular carcinoma (HCC) - are less likely to die or become too sick for a transplant while waiting for a new liver than those with other complications of end-stage liver disease, according to new research from the Perelman School of Medicine at the University of Pennsylvania.

29 Mar 2012

New McMaster centre to track health differences by ethnicity

Tracking health differences by ethnicity is the cornerstone of the new Chanchlani Research Centre at McMaster University.

29 Mar 2012

Change in registry protocols leads to underreporting of myeloid malignancies

Researchers at Moffitt Cancer Center in Tampa, Fla., and colleagues from the UF Shands Cancer Center in Gainesville, Fla., have found that cases of myeloid malignancies are being underreported since a change in registry protocols and laboratory practices starting in 2001.

29 Mar 2012

Biochemists determine atomic structure of new ABC transporter

Proteins belonging to the large and important family of ABC transporters have been associated with metabolic diseases and can cause resistance to antibiotics. Biochemists from the University of Zurich and the NCCR Structural Biology have succeeded in determining the atomic structure of a new ABC transporter. The insights gained could give rise to new therapies to treat multi-resistant bacteria, cystic fibrosis or gout, for instance.

29 Mar 2012

BHECN designs new online training modules to treat mental health issues

It's estimated that more than half of all U.S. mental health care takes place at the primary care level and that percentage jumps considerably in rural areas where there often are no mental health practitioners for hundreds of miles. New online training modules have been designed by the Behavioral Health Education Center of Nebraska (BHECN) to help primary care providers better treat patients with mental health issues.

29 Mar 2012

JDRF, iCo Therapeutics partner for iCo-007 Phase II trial in DME

iCo Therapeutics, a Vancouver-based drug reprofiling company and JDRF, the largest charitable funder of type 1 Diabetes (T1D) research have joined forces to investigate a potential new treatment for one of the most common complications of diabetes, diabetic macular edema.

29 Mar 2012

Ember, Joslin aims to utilize brown fat for treatment of obesity and diabetes

Joslin Diabetes Center and Ember Therapeutics, Inc. today announced an agreement aimed at utilizing "brown fat," a type of fat that helps increase energy expenditure within the body, as a novel technique for managing obesity and diabetes. Joslin's Chief Academic Officer, Dr. Ronald Kahn and other Joslin faculty, Drs. Yu-Hua Tseng and Aaron Cypess, have performed pioneering work in this field over the past several years, and were the first to show that a natural protein called BMP7 can help modulate the levels of brown fat.

29 Mar 2012

Increasing incidences of brain tumours calls for more spend on vital research

With more children and people under the age of 40 dying of a brain tumour than any other cancer in the United Kingdom, a leading researcher at Queen's University Belfast is calling for an increase in spending on vital research.

29 Mar 2012

Broad Institute, Novartis develop cancer cell line encyclopedia

Novartis and the Broad Institute have developed a cancer cell line encyclopedia that catalogues the genetic and molecular profiles of almost 1,000 human cancer cell lines used in drug research and development. Results of the collaboration, published in the journal Nature and released in advance online today, may allow scientists around the world to use this information to improve cancer clinical trial design and further cancer research.

29 Mar 2012

Navidea announces data from Lymphoseek Phase 3 study on oral and squamous cell cancers

Navidea Biopharmaceuticals, Inc., a specialty pharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that data from its Phase 3 clinical study investigating 99m-Tc-Tilmanocept in oral and squamous cell cancers (SCC) were presented as a poster presentation at the 65th Annual Cancer Symposium of the Society of Surgical Oncology (SSO) meeting held in Orlando, Florida, March 21-24, 2012.

29 Mar 2012

Depression more prevalent among stroke and transient ischemic attack survivors

Depression is more prevalent among stroke and transient ischemic attack survivors than in the general population, researchers reported in the American Heart Association's journal Stroke.

29 Mar 2012

New treatment approach halts spread of cancer cells into normal brain tissue

Treating invasive brain tumors with a combination of chemotherapy and radiation has improved clinical outcomes, but few patients survive longer than two years after diagnosis. The effectiveness of the treatment is limited by the tumor's aggressive invasion of healthy brain tissue, which restricts chemotherapy access to the cancer cells and complicates surgical removal of the tumor.

29 Mar 2012

DaVita thanks nearly 1,500 renal social workers during NASW

DaVita Inc., a leading provider of kidney care services that is committed to improving the quality of life for those diagnosed with chronic kidney disease (CKD), today thanks its nearly 1,500 social workers for the value and care they provide to patients and their families.

29 Mar 2012

Providing nutritional information may not be encouraging healthy eating habits

A study by Universit- Laval's Maurice Doyon and French and American researchers shows that U.S. consumers know surprisingly more about the fat content of the foods they buy than their French counterparts. Paradoxically, the obesity rate is nearly three times higher in the United States (35%) than it is in France (12%).

29 Mar 2012